Compare Futu Holdings Ltd (FUTU) vs Pfizer Inc (PFE) Price & Performance

FUTU Holdings trades at $98.13, up 1.85% with a bullish technical signal despite mixed earnings. The company shows strong fundamentals with 2025 revenue of $22.85B and net income of $11.34B, supported by robust profitability margins. However, recent quarterly earnings misses and ongoing securities class action lawsuits create significant headwinds.

While valuation metrics appear reasonable with P/E of 10.98 and analyst consensus leaning bullish (58% buy ratings), investors face substantial legal and regulatory risks. The stock's near-term trajectory will depend on Q2 2026 earnings results and resolution of multiple class action lawsuits alleging securities fraud violations.

Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.

Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.